Phase III Study of HUC3-637 Eye Drops for Adults With Primary Open Angle Glaucoma or Ocular Hypertension

What this Trial Is About

Researchers are conducting a multicenter, randomized, single-blind phase III clinical trial to assess the efficacy and safety of HUC3-637 for patients diagnosed with primary open angle glaucoma or ocular hypertension. This study aims to compare HUC3-637 with an active comparator to better understand its effects on eye pressure related to these conditions. Participants will receive either HUC3-637 or HUC3-637-R, both administered as ophthalmic solutions directly into the eye. These treatments involve topical ocular administration, and the study is designed to actively control and monitor the effects of these drugs on the patients conditions. During the study, researchers will evaluate the mean change in diurnal intraocular pressure over a 12-week period. Participants will be closely monitored for safety and treatment response throughout the trial duration, which starts in January 2026 and is expected to end in December 2027. The trial includes randomized allocation and single-blind masking to ensure reliable results.

Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension